Bispecific antibody · Immune activation, directed at CD3 (CD3E) and CD20 (MS4A1) · developed by Xencor
Plamotamab is a bispecific, Fc domain-containing monoclonal antibody that binds human CD3 on T cells and CD20 on B-lineage tumor cells. The cross-linking is intended to trigger a cytotoxic T-lymphocyte response against CD20-expressing B cells. It is studied in B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia and diffuse large B-cell lymphoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05328102 | Phase 2 | Diffuse Large-cell B-cell Lymphoma | Terminated | XNCR |
| NCT02924402 | Phase 1 | B-cell Non-Hodgkins Lymphoma | Completed | XNCR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
B-cell Non-Hodgkins LymphomaChronic Lymphocytic LeukemiaDiffuse Large-cell B-cell Lymphoma
See XNCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
XNCR catalysts and pipeline →